Spontaneous ADR reports as a trigger for pharmacogenetic research: A prospective observational study in the Netherlands

Drug Safety

Volumn 32, Issue 3, 2009, Pages 255-264

  Van Puijenbroek, Eugène ^a   Conemans, Jean ^b   Van Grootheest, Kees ^a  

^a NETHERLANDS PHARMACOVIGILANCE CENTRE LAREB   (Netherlands)

^b Hospital Pharmacy ZANOB   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; DNA DETERMINATION; DRUG SURVEILLANCE PROGRAM; FEASIBILITY STUDY; GENETIC COUNSELING; GENETIC POLYMORPHISM; GENOTYPE; HOSPITAL PHARMACY; HUMAN; MEDICAL RESEARCH; NETHERLANDS; PHARMACIST; PHARMACOGENETICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; UNSPECIFIED SIDE EFFECT;

ADVERSE DRUG REACTION REPORTING SYSTEMS; BIOMEDICAL RESEARCH; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HUMANS; NETHERLANDS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHARMACY SERVICE, HOSPITAL; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES;

EID: 63849266048     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200932030-00008     Document Type: Article

References (18)

1. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329 (7456): 15-9
2. van Grootheest AC. Improving pharmacovigilance and the role of the pharmacist [thesis]. Groningen: Rijksuniversiteit Groningen, 2003
3. Phillips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001; 286 (18): 2270-79
4. Jaquenoud SE, van der Velden JW, Rentsch K, et al. Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. Drug Saf 2006; 29 (9): 735-68
5. MedDRA. MedDRA and MSSO website 2007 [online]. Available from URL: http://www.meddramsso.com/MSSOWeb/index.htm [Accessed 2007 Dec 1]
6. WHO Collaborating Centre for Drug Statistics Methodology. WHO Collaborating Centre for Drug Statistics Methodology 2007 [online]. Available from URL: http://www.whocc.no/atcddd/ [Accessed 2007 Dec 1]
7. Flockhart DA. Drug interactions: cytochrome P450 system [online]. Available from URL: http://medicine iupui edu/flockhart/2007 [Accessed 2007 Dec 1]
8. Steen VM, Andreassen OA, Daly AK, et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995; 5 (4): 215-23
9. Lovlie R, Daly AK, Molven A, et al. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 1996; 392 (1): 30-4
10. de Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269 (22): 15419-422
11. Steward DJ, Haining RL, Henne KR, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997; 7 (5): 361-67
12. Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The roleof the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6 (4): 341-49
13. European Commission. Pharmacovigilance for medicinal products for human use volume 9A (version September 2008) [online]. Available from URL: http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-9/pdf/vol9a-09-2008. pdf [Accessed 2009 Feb 12]
14. Swen JJ, Wilting I, de Goede AL, et al. Pharmacogenetics: from bench to byte. Clin Pharmacol Ther 2008; 83 (5): 781-7
15. Ingelman-Sundberg M. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med 2008; 358 (6): 637-9
16. Clark DW, Donnelly E, Coulter DM, et al. Linking pharmacovigilance with pharmacogenetics. Drug Saf 2004; 27 (15): 1171-84
17. Clark DW, Morgan A, Hananeia L. Drug metabolism genotypes and their associations with adverse drug reactions in selected populations: a pilot study of methodology. Pharmacoepidemiol Drug Saf 2000; 9 (393): 400
18. De Bruin ML, van Puijenbroek EP, Bracke M, et al. Pharmacogenetics of drug-induced arrhythmias: a feasibility study using spontaneous adverse drug reactions reporting data. Pharmacoepidemiol Drug Saf 2006; 15 (2): 99-105